Sign In
Buy OST
$1.70
+0 (+0%)
At Close: Jun 03, 2026
Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September 2025 New York, New York--(Newsfile Corp. -
New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate bi
OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
06:00am, Tuesday, 19'th Aug 2025
U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in preparation for Accelerated Approval submission follow
MHRA seeks to harmonize UK & US regulatory review via Project Orbis EMA Rapporteur Scientific Advice Meeting scheduled for October 2025 New York, New York--(Newsfile Corp. - August 7, 2025) - OS Thera
Ostin Technology Group Co., Ltd. Announces 1-for-25 Reverse Share Split Effective August 5, 2025
08:30am, Monday, 28'th Jul 2025
Nanjing, China, July 28, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (NASDAQ:OST), a leading supplier of display modules and polarizers based in China, today announced th
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today anno
New York, July 01, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York,
Ostin Technology Group Co., Ltd. Announces $5 Million Registered Direct Offering
09:15am, Monday, 30'th Jun 2025
Nanjing, China, June 30, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (“the Company”) (Nasdaq: OST), a leading supplier of display modules and polarizers based in China today announce
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today anno
Ostin Technology Group Co Ltd Issues Statement Regarding Market Activity
10:40am, Friday, 27'th Jun 2025
Nanjing, China, June 27, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (“the Company”) (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, issued the fo
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today anno
NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today an
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
06:00am, Thursday, 15'th May 2025
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today anno
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today anno
Ostin Technology Group Announces Pricing of $5.0 million Registered Direct Offering
04:30pm, Tuesday, 15'th Apr 2025
Nanjing, China, April 15, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (“the Company”) (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, today announ
